SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a next-gen biopharma company combining automated, experimental biology with artificial intelligence to discover and develop drugs at scale, today announced ...

Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning. The round was led by ...

Hi guys. I'm new here. I've joined these forums due to a recommendation from a friend of mine. He says that you guys here can offer some good programming repair work if guys like me are in trouble.

Beyond rare diseases and oncology, Recursion’s pipeline includes two candidates. One is REC-3964, an oral, non-antibiotic small molecule designed to treat Clostridioides difficile (C. diff) by ...